Another limitation of our study is that the TLR4 signaling mechanisms (including downstream components of TLR4 signaling cascade, e.g., MyD88, TRIF) involved in ME-associated BC progression remain insufficiently explored. This evidence concerns the gene MYD88 and breast cancer.